ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 0526 • ACR Convergence 2022

    Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial

    Lynn Fussner1, Luis Felipe Flores-Suarez2, Rodrigo Cartin-Ceba3, Ulrich Specks3, P. Gerard Cox4, David Jayne5, Peter Merkel6 and Michael Walsh4, 1The Ohio State University, Columbus, OH, 2Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico, 3Mayo Clinic, Rochester, MN, 4McMaster University, Hamilton, ON, Canada, 5University of Cambridge, Cambridge, United Kingdom, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
  • Abstract Number: 1237 • ACR Convergence 2022

    Assessment of Common Femoral Vein Intima-Media Thickness by Ultrasound in Behçet’s Disease: Comparative Study of Patients with or Without Vascular Involvement in a National Referral Center

    Diana Prieto-Peña1, Alfonso del Peral-Fanjul2, Belén Atienza-Mateo1, Veronica Pulito-Cueto1, Miguel Ángel González-Gay3 and Ricardo Blanco4, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, 3Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Clinical vascular involvement is present in up to 40% of patients with Behçet’s disease (BD). Increased venous wall thickness assessed with ultrasound (US) has…
  • Abstract Number: 1561 • ACR Convergence 2022

    Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

    Didar Ucar1, Basak Ecem Bircan2, Nigar Rustamli3, Bilge Batu Oto1, Vedat Hamuryudan4, Sinem Nihal Esatoglu5 and gulen Hatemi5, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells on slit lamp examination at the time of diagnosis. However, the prognostic…
  • Abstract Number: 1619 • ACR Convergence 2022

    Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities

    Eugenio De Miguel1, PIERLUIGI MACCHIONI2, Edoardo Conticini3, Corrado Campochiaro4, Rositsa Karalilova5, Sara Monti6, Cristina Ponte7, Giulia Klinowski2, Irene Monjo8, Paolo Paolo Falsetti3, Anastas Batalov9, alessandro tomelleri4 and Alojzija Hocevar10, 1Hospital Universitario La Paz, Madrid, Spain, 2IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 3Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, 4IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, 7Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, 8Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, 9Medical University of Plovdiv, Plovdiv, Bulgaria, 10University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of patients with GCA. In a…
  • Abstract Number: L15 • ACR Convergence 2021

    A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach

    Alexandre Boissais1, Hélène Blasco2, Patrick Emond3, Antoine Lefevre2, Adrien Bigot4, denis Mulleman5, François Maillot4 and Alexandra Audemard-Verger4, 1Medical University of Tours, Tours, France, 2Biochemistry and Molecular Biology Department, Tours, France, 3In vitro Nuclear Medicine Department, Tours, France, 4Department of Internal Medicine, Tours, France, 5Rheumatology Department, Tours, France

    Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic…
  • Abstract Number: L21 • ACR Convergence 2021

    Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial

    Benjamin Terrier1, Gregory Pugnet2, Claire de Moreuil3, Bernard Bonnotte4, Ygal Benhamou5, Elisabeth Diot6, Dominique Chauveau2, Pierre Duffau7, Nicolas Limal8, Antoine Neel9, Geoffrey Urbanski10, Noemie Jourde-Chiche11, Nicolas Martin-Silva12, Francois Maurier13, Arsene Mekinian14, Nicolas Schleinitz11, Felix Ackermann15, Anne-Laure Fauchais16, Antoine Froissart17, Thomas Le Gallou18, Yurdagul Uzunhan19, Jean-Francois Viallard7, Alice Berezne20, Laurent Chiche21, Bruno Crestani14, Guillaume Direz22, Cecile-Audrey Durel23, Pascal Godmer24, Jean-Emmanuel Kahn25, Marc Lambert26, Thomas Quemeneur27, Jacques Cadranel14, Pierre Charles28, Antoine Dossier14, Lea Jilet29, Loic Guillevin14, Hendy Abdoul29 and Xavier Puechal14, 1Cochin Hospital, Paris, France, 2CHU, Toulouse, France, 3CHU, Brest, France, 4CHU, Dijon, France, 5CHU, Rouen, France, 6CHU, Tours, France, 7CHU, Bordeaux, France, 8CHU, Creteil, France, 9CHU, Nantes, France, 10CHU, Angers, France, 11CHU, Marseille, France, 12CHU, Caen, France, 13CH, Metz, France, 14CHU, Paris, France, 15Hopital Foch, Suresnes, France, 16CHU, Limoges, France, 17CHIC, Creteil, France, 18CHU, Rennes, France, 19CHU, Bobigny, France, 20CH, Annecy, France, 21CH, Marseille, France, 22CH, Le Mans, France, 23CHU, Lyon, France, 24CH, Vannes, France, 25CHU, Boulogne, France, 26CHRU, Lille, France, 27CH, Valenciennes, France, 28CH, Paris, France, 29URC, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…
  • Abstract Number: 0952 • ACR Convergence 2021

    Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

    Sebastian Sattui1, Richard Conway2, Michael Putman3, Andrea Seet4, Kaley Beins5, Catherine Hill6, David Liew7, Sarah Mackie8, Puja Mehta9, Lorna Neill10, Gimena Gomez11, Maria Salinas12, Federico Maldonado13, Henrique Moriz14, Samia Studart15, NAFICE ARAUJO16, Ann Knight17, Davide Rozza18, Luca Quartuccio19, Maxime Samson20, Stephane Bally21, Alexandre Maria22, Pascal Chazerain23, Rebecca Hasseli24, Ulf Müller-Ladner25, Bimba Franziska Hoyer26, Reinhard Voll27, Rita Pinheiro Torres28, Mariana Luis29, Sandra Lúcia Ribeiro30, Samar Al Emadi31, Jeffrey Sparks32, Tiffany Hsu33, Kristin D'Silva34, Naomi Patel34, Leanna Wise35, Emily Gilbert36, Maria Valenzuela-Almada37, Ali Duarte-Garcia38, Manuel Ugarte-Gil39, Emily Sirotich40, Jean Liew41, Jonathan Hausmann42, Paul Sufka43, Suleman Bhana44, Rebecca Grainger45, Wendy Costello46, Lindsay Jacobsohn47, Zara Izadi4, Anja Strangfeld48, Elsa Frazão Mateus49, Kimme Hyrich50, Laure Gossec51, Loreto Carmona52, Saskia Lawson-Tovey50, Lianne Kearsley-Fleet53, Martin Schaefer54, Milena Gianfrancesco4, Pedro Machado55, Zachary Wallace34, Jinoos Yazdany4 and Philip Robinson56, 1Hospital for Special Surgery, New York, NY, 2St. James's University Hospital, Dublin, Ireland, 3Medical College of Wisconsin, Brookfield, WI, 4University of California San Francisco, San Francisco, CA, 5Vasculitis Foundation, Kansas City, MO, 6Queen Elizabeth Hospital, Woodville, Australia, 7Austin Health, Heidelberg, Australia, 8School of Medicine, University of Leeds, Leeds, United Kingdom, 9University College London, London, United Kingdom, 10PMR GCA Scotland, Perth, United Kingdom, 11Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 12Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 13Sanatorio Güemes, Buenos Aires, Argentina, 14Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, 15HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, 16Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, 17Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, 18Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, 19Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 20CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, 21Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, 22Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, 23Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, 24Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, 25JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, 26Universittsklinikum Schleswig-Holstein, Kiel, Germany, 27Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 28Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, 29Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, 30Universidade Federal do Amazonas, Amazonas, Brazil, 31Hamad medical corporation, Doha, Qatar, 32Brigham and Women's Hospital, Boston, MA, 33Brigham and Women's Hospital, Jamaica Plain, MA, 34Massachusetts General Hospital, Boston, MA, 35LAC+USC/Keck Medicine of USC, Pasadena, CA, 36Mayo Clinic, Jacksonville, FL, 37Division of Rheumatology, Mayo Clinic, Rochester, MN, 38Mayo Clinic, Rochester, MN, 39Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 40McMaster University, Hamilton, ON, Canada, 41Boston University, Boston, MA, 42Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 43HealthPartners, Eagan, MN, 44Crystal Run Health, Montvale, NJ, 45University of Otago, Wellington, New Zealand, 46Irish Children's Arthritis Network, Bansha, Ireland, 47University of California San Francisco, Antioch, CA, 48Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 49Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 50University of Manchester, Manchester, United Kingdom, 51Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 52Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 53Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 54German Rheumatism Research Center, Berlin, Germany, 55Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 56University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia

    Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
  • Abstract Number: 1412 • ACR Convergence 2021

    Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

    Lara Sánchez-Bilbao1, Javier Loricera1, Juan Pablo Valdivieso Achá2, Clara Moriano3, Javier Narvaez4, Vicente Aldasoro5, Olga Maíz6, Rafael Melero7, Juan Ignacio Villa8, Paloma Vela9, Susana Romero-Yuste10, José Luis Callejas11, Eugenio De Miguel12, Eva Galindez-Agirregoikoa13, Francisca Sivera14, Jesús Carlos Fernández-López15, Carles Galisteo16, Iván Ferraz-Amaro17, Juan Carlos Nieto18, Juan Ramón de Dios19, Julio Sánchez20, Esther Fernández21, Isabel de la Morena22, Patricia Moya23, Roser Solans-Laqué24, Jose Luis Andreu25, Marcelino Revenga26, Valvanera Pinillos27, Andrea García-Valle28, Adela Gallego29, Carlota Iñíguez30, Cristina Hidalgo31, Noemí Garrido-Puñal32, Ruth López-González33, José Andrés Román-Ivorra34, Sara Manrique Arija35, Paz Collado36, Enrique Raya11, Francisco Navarro37, Antoni Juan Mas38, Carmen Ordas39, Maria Dolors Boquet40, Noelia Álvarez-Rivas41, Maria Luisa Velloso-Feijoo42, Cristina Campos-Fernández43, Íñigo Rúa-Figueroa44, Arantxa Conesa45, Eva Salgado46, Miguel Ángel gonzalez-Gay47 and Ricardo Blanco48, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario La Princesa, Madrid, Spain, 3Hospital Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Complejo Hospitalario de Navarra, Pamplona, Spain, 6Hospital Universitario de Donostia, San Sebastián, Spain, 7Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 8Hospital Sierrallana, Torrelavega, Spain, 9Hospital General Universitario de Alicante, Alicante, Spain, 10Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 11Hospital San Cecilio, Granada, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Hospital Universitario de Basurto, Bilbao, Spain, 14Hospital Universitario de Elda, Alicante, Spain, 15Hospital Universitario Juan Canalejo, A Coruña, Spain, 16Hospital Universitari Parc Tauli, Saadell, Spain, 17Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 18Hospital General Universitario Gregorio Marañón, Madrid, Spain, 19Hospital Universitario de Araba, Mondragón, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 22Hospital Clínico Universitario de Valencia, Valencia, Spain, 23Hospital Sant Pau, Barcelona, Spain, 24Hospital Vall d'Hebron, Barcelona, Spain, 25Hospital Universitario Puerta de Hierro, Madrid, Spain, 26Hospital Ramón y Cajal, Madrid. Spain., Madrid, Spain, 27Hospital San Pedro, Logroño, Spain, 28Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, 29Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 30Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 31Hospital Universitario Salamanca, Salamanca, Spain, 32Hospital Universitario Virgen del Rocío, Sevilla, Spain, 33Complejo Hospitalario de Zamora, Zamora, Spain, 34Hospital Universitario y Politécnico La Fe, Valencia, Spain, 35Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 36Hospital Universitario Severo Ochoa, Madrid, Spain, 37Hospital General Universitario de Elche, Elche, Spain, 38Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 39Hospital de Cabueñes, Gijón, Spain, 40Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, 41Hospital San Agustín, Aviles, Spain, 42Hospital Universitario de Valme, Sevilla, Spain, 43Consorci Hospital General Universitari de Valencia, Valencia, Spain, 44Hospital Universitario Doctor Negrín, Gran Canaria, Spain, 45Hospital Universitario de Castellón, Castellón, Spain, 46Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 47Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 48Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…
  • Abstract Number: 1876 • ACR Convergence 2021

    A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome

    Yiming Luo1, Ertugrul Bolek1, Kaitlin Quinn2, Kristina Wells3, Emily Rose4, Emily Rominger1, Levent Kilic5, Omer Karadag6, Cindy Clark1, Alicia Livinski1, Peter Grayson7 and Marcela Ferrada1, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Case Western, Cleveland Heights, OH, 5Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 6Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, 7National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare and poorly understood entity with clinical features of both relapsing polychondritis (RP)…
  • Abstract Number: 1010 • ACR Convergence 2021

    Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease

    Paul Tsoukas1, Melissa Kleinau2, Lysa Langevin2, Lily Morikawa3, Trang Duong1, Suzanne Tam4 and Rae Yeung5, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, 4Hospital for Sick Children, Toronto, ON, 5The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL)…
  • Abstract Number: 1413 • ACR Convergence 2021

    Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

    Mark Matza1, Adam Jarvie2, Ana Fernandes1, John Stone3 and Sebastian Unizony4, 1Massachusetts General Hospital, Boston, MA, 2Masssachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Winchester, MA

    Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis…
  • Abstract Number: 1877 • ACR Convergence 2021

    Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics

    Yiming Luo1, Kaitlin Quinn2, Marcela Ferrada1, Elaine Novakovich1 and Peter Grayson3, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and…
  • Abstract Number: 1047 • ACR Convergence 2021

    Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain

    ana Perez1, Arturo Rodriguez Pérez2, Pablo Fernandez-Navarro3, Fernando Albarran4, Cristina Bohorquez4, Atusa Movasat4, Lucia Ruiz4, Paula Pretel4, elena Rabadan4, Valentina Emperiale4, Adrian abbasi5, julio suarez5, Lorena Montano4, emilio rico5, alfredo prieto2, melchor Alvarez de Mon5 and beatriz perez3, 1Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, 2Faculty of Medicine. Alcala University, Alcala de Henares, Spain, 3Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, 4Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, 5Hospital Universitario Príncipe de Asturias, Madrid, Spain

    Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
  • Abstract Number: 1414 • ACR Convergence 2021

    The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States

    Mark Matza1, Karina Torralba2 and Minna Kohler3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
  • Abstract Number: 1880 • ACR Convergence 2021

    Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young3, Cristina Burroughs4 and Peter Merkel5, 1Vanderbilt University Medical Center, Franklin, TN, 2University of California Los Angeles, West Hills, CA, 3Vasculitis Foundation, Kansas City, MO, 4Health Informatics Institute, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology